FDA clearance of the first Alzheimer's blood test marks a significant step toward earlier, more straightforward diagnosis—potentially improving care for adults with memory concerns.
Extreme weather events, the increasing threat of antimicrobial resistance, and other global challenges are impacting the prevalence and fight against tuberculosis. Open Access Government examines the burden of TB, looking at the origins and drivers of this ubiquitous disease
A major UK Biobank study shows that inconsistent sleep timing, not just sleep duration, is associated with increased risk for 172 diseases, including liver cirrhosis and cardiovascular conditions.
New research from the University of Nottingham shows the COVID-19 pandemic may have accelerated brain ageing by over five months, even in people who were never infected, due to stress and lifestyle changes.
A University of Cambridge study reveals that prolonged outdoor air pollution exposure is associated with a significantly increased risk of developing dementia.
A major £40 million investment will drive pioneering research at the University of Edinburgh, aiming to transform diagnosis and treatment for conditions such as autism, fragile X syndrome, and ADHD.
New research shows that exposure to PFAS chemicals may increase the risk of type 2 diabetes by disrupting metabolism and affecting blood sugar regulation.
The UK Government has unveiled an enhanced support plan for people with ME/CFS, including NHS staff training, public awareness campaigns, and up to £200,000 in grants per research project.
The University of Liverpool is leading a £2.7 million clinical trial to investigate vagus nerve stimulation as a treatment for people with drug-resistant epilepsy.
A University of Bristol study finds trained detection dogs can identify Parkinson's disease with up to 98% accuracy by smelling skin swabs, offering promise for early, non-invasive diagnosis.
A new University of Manchester study finds that analysing skin sebum via non-invasive swabs can identify Parkinson's biomarkers up to seven years before motor symptoms emerge, offering hope for earlier detection and intervention.
A University of South Australia team has developed a weekly biodegradable injection of levodopa and carbidopa, offering seven-day release to ease dosing and boost adherence for Parkinson’s patients.
